A 2 × 2 factorial, randomised, open-label trial to determine the clinical and cost-effectiveness of hypertonic saline (HTS 6%) and carbocisteine for airway clearance versus usual care over 52 weeks in adults with bronchiectasis: a protocol for the CLEAR clinical trial

BACKGROUND: Current guidelines for the management of bronchiectasis (BE) highlight the lack of evidence to recommend mucoactive agents, such as hypertonic saline (HTS) and carbocisteine, to aid sputum removal as part of standard care. We hypothesise that mucoactive agents (HTS or carbocisteine, or a...

Descripción completa

Detalles Bibliográficos
Autores principales: Bradley, Judy Martina, Anand, Rohan, O’Neill, Brenda, Ferguson, Kathryn, Clarke, Mike, Carroll, Mary, Chalmers, James, De Soyza, Anthony, Duckers, Jamie, Hill, Adam T., Loebinger, Michael R., Copeland, Fiona, Gardner, Evie, Campbell, Christina, Agus, Ashley, McGuire, Alistair, Boyle, Roisin, McKinney, Fionnuala, Dickson, Naomi, McAuley, Danny F., Elborn, Stuart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6921594/
https://www.ncbi.nlm.nih.gov/pubmed/31856887
http://dx.doi.org/10.1186/s13063-019-3766-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6921594/
https://www.ncbi.nlm.nih.gov/pubmed/31856887
http://dx.doi.org/10.1186/s13063-019-3766-9

Ejemplares similares